Basit öğe kaydını göster

dc.contributor.authorGEDİKBAŞI, Asuman
dc.contributor.authorKumbasar, Abdulbaki
dc.contributor.authorHursitoglu, Mehmet
dc.contributor.authorAcarer, Didem
dc.contributor.authorHarmankaya, Ozlem
dc.contributor.authorOKUTURLAR, Yıldız
dc.contributor.authorGunaldi, Meral
dc.contributor.authorKocoglu, Hakan
dc.date.accessioned2021-03-02T22:55:28Z
dc.date.available2021-03-02T22:55:28Z
dc.identifier.citationOKUTURLAR Y., Gunaldi M., Kocoglu H., Hursitoglu M., GEDİKBAŞI A., Acarer D., Harmankaya O., Kumbasar A., "Serum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer", JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.14, 2018
dc.identifier.issn0973-1482
dc.identifier.othervv_1032021
dc.identifier.otherav_0f7fa1d8-4174-4607-aed6-e1bf454525b0
dc.identifier.urihttp://hdl.handle.net/20.500.12627/15959
dc.identifier.urihttps://doi.org/10.4103/0973-1482.235355
dc.description.abstractAim: The aims of this study are to evaluate the serum levels of paraoxonase (PON) and arylesterase (ARE) in breast cancer (BC) patients; to determine their relationship with chemotherapy requirements in BC; and to find a cut-off value to assess subjects with a higher risk of BC.
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleSerum paraoxonase and arylesterase can be useful markers to predict neoadjuvant chemotherapy requirement in patients with breast cancer
dc.typeMakale
dc.relation.journalJOURNAL OF CANCER RESEARCH AND THERAPEUTICS
dc.contributor.departmentBakirkoy Dr. Sadi Konuk Research & Training Hospital , ,
dc.identifier.volume14
dc.contributor.firstauthorID2214745


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster